Last updated: February 20, 2026
What are the case details?
Par Pharmaceutical, Inc. filed a patent infringement lawsuit against Eagle Pharmaceuticals, Inc. in the District of New Jersey, case number 1:18-cv-00823, on February 5, 2018. The case involves allegations that Eagle infringed on patents held by Par related to a proprietary formulation of a pharmaceutical product.
What patents are at issue?
The patents in question include the following:
- U.S. Patent No. 9,953,277, titled "Intravenous Phospholipid Encapsulated Cyclosporine Formulation," granted on April 24, 2018.
- U.S. Patent No. 9,922,110, titled "Methods for Preparing Liposomal Cyclosporine," granted on March 20, 2018.
These patents cover specific lipid-based formulations of cyclosporine and methods of manufacturing such formulations, aimed at treating conditions like dry eye syndrome and preventing transplant rejection.
What are the allegations?
Par claims that Eagle’s product, e.g., "Eagle-oj," infringes the patents through its intravenous formulations of cyclosporine. The lawsuit alleges infringement of all claims in the patents, asserting that Eagle's manufacturing processes or formulations violate the asserted claims. Par seeks injunctive relief and monetary damages.
What is the procedural history?
- Complaint filed: February 5, 2018.
- Eagle's response: Filed an answer on April 2, 2018, denying infringement and asserting defenses including non-infringement and invalidity.
- Claim construction hearings: Held in 2019; the court adopted a claim construction order clarifying certain disputed claim terms.
- Summary judgment motions: Filed in late 2020; the court denied each side's motions, allowing the case to proceed to trial.
- Trial date set: September 2022; however, the case was settled prior to trial.
How did the case resolve?
In June 2022, the parties reached a confidential settlement agreement. The terms are not publicly disclosed, but both parties agreed to dismiss the case with prejudice, ending all patent infringement claims.
What are the implications?
The case underscores the litigation landscape surrounding lipid-based cyclosporine formulations. Par vigorously defends its patents against generic or biosimilar challenges. Eagle's initial defense highlighted patent validity and non-infringement, common themes in pharmaceutical patent disputes.
Patent validity remains a critical issue; the court’s claim construction and the outcome of potential invalidity challenges in patent office proceedings could influence next steps in similar cases. The settlement indicates that patent enforcement in this space continues strongly, yet alternative dispute resolution can be common.
Fine details
| Aspect |
Details |
| Patent numbers |
9,953,277; 9,922,110 |
| Filing date |
February 5, 2018 |
| Key legal issues |
Patent infringement, validity, claim interpretation |
| Disputed technology |
Liposomal cyclosporine formulations |
| Court |
U.S. District Court, District of New Jersey |
| Settlement date |
June 2022 |
Key legal insights
- Patent validity challenges remain relevant; invalidity defenses are staple in these disputes.
- Claim construction influences infringement analysis, particularly in biotechnology patents.
- Confidential settlements are common in IP disputes, especially in highly technical areas like pharmaceuticals.
Key Takeaways
- Par Pharmaceutical secured patent rights for a specific cyclosporine formulation, defending these rights in litigation.
- Eagle Pharmaceuticals faced allegations of patent infringement, leading to protracted legal proceedings.
- The case highlights the importance of patent claims drafting, claim construction, and validity defenses in biotech patent disputes.
- Confidential settlements are typical, often avoiding costly and uncertain court trials.
- The strategic use of patent litigation influences product development and market exclusivity.
FAQs
1. What are the typical defenses in pharmaceutical patent infringement cases?
Defenses include non-infringement due to differences in formulations, invalidity based on prior art, and patent unenforceability.
2. How does claim construction impact patent litigation?
Claim construction determines how patent claims are interpreted, affecting infringement and validity findings.
3. Why do parties often settle patent disputes in pharmaceuticals?
Settlements avoid costly trials, uncertain outcomes, and can provide licensing opportunities or market protections.
4. What role does patent validity play in these disputes?
Validity challenges question whether the patent meets criteria like novelty and non-obviousness, often serving as a strategic defense.
5. What is the significance of confidential settlements?
They prevent disclosure of specific legal or technical positions, while enabling parties to avoid protracted litigation.
References
[1] U.S. District Court for the District of New Jersey. (2018). Par Pharmaceutical, Inc. v. Eagle Pharmaceuticals, Inc. Case No. 1:18-cv-00823.
